EXPERIMENTAL MODELING OF MULTIPLE SCLEROSIS:
THE RESULTS OF CORRECTIVE ACTION OF ACTIVE ANTIOXIDANT

I.V. Okunevich
Institute of Experimental Medicine, Saint Petersburg, Russia

ЭКСПЕРИМЕНТАЛЬНАЯ МОДЕЛЬ РАССЕЯННОГО СКЛЕРОЗА:
РЕЗУЛЬТАТЫ КОРРЕКЦИИ АКТИВНЫМИ АНТИОКСИДАНТАМИ

И.В. Окуневич
ФГБНУ «Институт экспериментальной медицины», Санкт-Петербург

Comprehensive treatment of patients with multiple sclerosis (MS) is still relevant. The complex pathogenesis and acute incidence of MS in young people requires the use of multifunctional drugs with a protective effect, including antioxidants. The purpose of this study is to identify a corrective neuroprotective and immune modulating effect of the synthetic drug Triafen-2 (Trf-2), obtained in optimized way. Trf-2 was used at a dose of 50 mg/kg orally with chronic administration in II parts of experiments. To create an adequate model of MS — autoimmune encephalomyelitis (EAE), immunization of guinea pigs with an encephalitic mixture was used in Freund’s complete adjuvant. Mortality, a number of immunological parameters, the clinical picture of neurological complications and the severity of CNS damage in guinea pigs were determined. We studied morphologically the development of T-lymphocytic infiltration of the brain and spinal cord, demyelination of nerve fibers, the degree of cerebellar disorders, disorders of the pelvic organs, the presence of paresis and paralysis. A significant decrease in mortality was shown and protective effect of Trf-2 on neurological symptoms of EAE was noted. The reduction and even complete absence of paresis and paralysis in 66.5% of guinea pigs in the experimental group compared with animals that did not receive treatment was determined. A positive effect of Trf-2 on the migration activity of leukocytes and antibodies in the blood was found. In the group with Trf-2, there was a decrease in the content of lipid hydroperoxides and malonic dialdehyde. A pronounced neuroprotective and immune modulating effect of Triafen-2, which inhibits pathological disorders in an experimental model of EAE, has been established. The results justify the need for further study of Triafen-2 as a promising corrective drug.

Keywords: experimental autoimmune encephalomyelitis; Triafen-2; protective effect.

Introduction. The main therapy of multiple sclerosis (MS) patients is aimed at stopping the autoimmune inflammatory process by immune modulating and anti-inflammatory drugs, since it is destructive damage to the myelin sheaths of the nerve fibers by the own immune system that leads to the development of neurological complications [1]. The multiplicity of regimens of MS dictates the need of new effective drugs. Due to the activation of oxidative stress in the complex therapy of MS,
the use of multifunctional drugs with antioxidant effect is justified. Earlier, we detected anti-inflammatory activity in antioxidant Hypoxen (Hpx) [2]. We explored another active compound — Triafen-2 (Trf-2) — the analog of Hpx, obtained in optimized way. Aim of the study — to identify the ability of Trf-2 to correct of immunological and neurological complications in the MS model.

**Material and methods.** The model of experimental autoimmune encephalitis (EAE) was used as the most adequate method of MS reproduction, which allows studying pathological processes in CNS. EAE was caused by a single subcutaneous inoculation into the paw pads of guinea pigs of encephalitogenic mixture — the main myelin protein in complete Freund’s adjuvant. A few days later the animals developed T-lymphocytic infiltration of the brain, demyelination of the nerve endings and paralysis occurred. The drug Trf-2 was orally administered at a dose of 50 mg/kg daily for 35 days. The experiments were carried out in I-II parts on 75 adult male guinea pigs (400–450 g). In part I, in 30 guinea pigs, mortality was determined after the inoculation of sensitizing agent and adding of Trf-2 was evaluated. In part II of experiments, a study was conducted on the effectiveness of Trf-2 in 45 guinea pigs, which were divided into 3 groups: 1 — intact, 2 — pathological model (EAE), 3 — EAE + Trf-2. The severity of the disease was assessed by clinical index in points from 0 to 6.

**Findings.** In the group of animals with the drug Trf-2, the frequency of detection of circulating complexes was the smallest, and the peak production of antibodies fell on the 21st day. The size of the migration zones of immunocompetent cells prevailed in the pathological group (EAE). The results obtained indicate the available immune protective ability of Trf-2. When analyzing the peripheral blood of experimental guinea pigs, decline of the accumulation of content: MDA (−30%) and hydro-peroxides (−29%) in group with Trf-2 treatment was shown.

**Conclusion.** The pathological process in MS — complex in nature and course, autoimmune reactions cause an inflammatory process and lead to diffuse degenerative changes in axons and neuron death, an excessive concentration of reactive oxygen forms and oxidative products occur. The model of EAE was the most adequate of MS reproduction and allowed to investigate new protective drugs.

**References**
